COMMUNIQUÉS West-GlobeNewswire

Genvor Announces Strategic Expansion into Health and Wellness Market, Leveraging Proprietary AI-Accelerated BioCypher Platform to Develop Consumer Peptide Solutions
04/03/2026
Company’s proprietary peptide platform expands beyond agriculture into human recovery, performance, and wellness Woodland, CA, March 04, 2026 (GLOBE NEWSWIRE) -- Genvor, Inc. (OTCQB: GNVR), a biotechnology company [...]
Pacira BioSciences to Participate in Fireside Chat at the Barclays 28th Annual Global Healthcare Conference
04/03/2026
BRISBANE, Calif., March 04, 2026 (GLOBE NEWSWIRE) -- Pacira BioSciences, Inc. (Nasdaq: PCRX), the industry leader in its commitment to deliver innovative, non-opioid pain therapies to transform the lives of patients, [...]
Vericel Announces FDA Approval of New State-of-the-Art Advanced Therapy Manufacturing Facility
04/03/2026
Company Achieves Significant Regulatory and Operational Milestone Substantially Increases Manufacturing Capacity to Support Long-Term Growth Enables Potential MACI Commercialization Outside of the U.S. CAMBRIDGE, Mass [...]
Ardelyx to Participate in Upcoming Investor Conferences
04/03/2026
WALTHAM, Mass., March 04, 2026 (GLOBE NEWSWIRE) -- Ardelyx, Inc. (Nasdaq: ARDX), a biopharmaceutical company focused on the development and commercialization of innovative medicines that meet significant unmet medical [...]
Elutia Regains Compliance with Nasdaq Listing Requirements
04/03/2026
GAITHERSBURG, Md., March 04, 2026 (GLOBE NEWSWIRE) -- Elutia Inc. (Nasdaq: ELUT) ("Elutia" or the "Company"), a pioneer in drug-eluting biomatrix technologies, today announced that it has received notice from Nasdaq [...]
Achieve Life Sciences Presents Data at SRNT Demonstrating Successful Cessation in Smokers with Extensive Prior Treatment Exposure; and on Participant Experience in the ORCA-OL Study
04/03/2026
A pooled Phase 3 analysis of more than 1,600 people who smoke showed high quit rates; including among those who had previously not succeeded with other smoking cessation medications and regardless of the number of prior [...]
SpyGlass Pharma to Participate in the Jefferies Biotech on the Beach Summit
04/03/2026
ALISO VIEJO, Calif., March 04, 2026 (GLOBE NEWSWIRE) -- SpyGlass Pharma, Inc. (Nasdaq: SGP) (“SpyGlass Pharma”), a late-stage biopharmaceutical company, today announced that members of the executive management team will [...]
Tevogen Announces Reverse Stock Split
04/03/2026
WARREN, N.J., March 04, 2026 (GLOBE NEWSWIRE) -- Tevogen (“Tevogen Bio Holdings Inc.” or “Company”) (Nasdaq: TVGN ) today announced that its Board of Directors (the “Board”) has approved a reverse stock split of its [...]
Boundless Bio to Participate in the Leerink Global Healthcare Conference
04/03/2026
SAN DIEGO, March 04, 2026 (GLOBE NEWSWIRE) -- Boundless Bio (Nasdaq: BOLD), a clinical-stage oncology company interrogating extrachromosomal DNA (ecDNA) biology to deliver transformative therapies to patients with [...]
Can-Fite’s Namodenoson Successfully Meets Primary Endpoint in Phase 2a Pancreatic Cancer Study
04/03/2026
Ramat Gan, Israel, March 04, 2026 (GLOBE NEWSWIRE) -- Can-Fite BioPharma Ltd. (NYSE American: CANF) (TASE: CANF), a clinical-stage biotechnology company developing a pipeline of proprietary small molecule drugs for the [...]
Rezolute to Participate in the Citizens Life Sciences Conference
04/03/2026
REDWOOD CITY, Calif., March 04, 2026 (GLOBE NEWSWIRE) -- Rezolute, Inc. (Nasdaq: RZLT) (“Rezolute” or the “Company”), a late-stage rare disease company focused on treating hypoglycemia caused by all forms of [...]
Fennec Pharmaceuticals Announces Clinical Research Collaboration with Tampa General Hospital Cancer Institute
04/03/2026
Study is Real-World Evaluation of the Clinical Utility of Sodium Thiosulfate Injection (PEDMARK®) in Reducing the Risk of Ototoxicity in Adolescent and Young Adult (AYA) and Adult Patients with Non-Metastatic Solid [...]
Cellectar Biosciences Reports Financial Results for Year Ended 2025 and Provides Corporate Updates
04/03/2026
On track to submit Conditional Marketing Authorization for iopofosine I 131 to European Medicines Agency in Q3 2026 for potential 2027 EU commercialization as a treatment for Waldenström Macroglobulinemia Initiated [...]
Dyadic and Fermbox Bio Launch First Product Under Expanded Collaboration: Animal-Origin-Free Recombinant DNase I (RNase-Free)
04/03/2026
JUPITER, Fla. and BENGALURU, India, March 04, 2026 (GLOBE NEWSWIRE) -- Dyadic Applied BioSolutions (“Dyadic”, “we”, “us”, “our”, or the “Company”) (NASDAQ: DYAI), a global biotechnology company producing precision- [...]
Alterity Therapeutics Appoints Daniel O. Claassen, M.D., M.S., as Chief Medical Advisor
04/03/2026
– Neurology and Movement Disorder Specialist Adds Deep Clinical and Development Expertise – MELBOURNE, Australia and SAN FRANCISCO, March 04, 2026 (GLOBE NEWSWIRE) -- Alterity Therapeutics (ASX: ATH, NASDAQ: ATHE) (“ [...]
Clearmind Medicine Moving Forward to the Next Stage of Its Clinical Trial Following Data and Safety Monitoring Board Approval
04/03/2026
The approval was granted based on additional topline positive safety results reinforcing favorable profile of CMND-100 in ongoing Phase I/IIa clinical trial Vancouver, Canada, March 04, 2026 (GLOBE NEWSWIRE) -- [...]
NervGen Pharma Appoints Shamim Ruff as Chief Regulatory Affairs Officer and Christine McSherry as SVP, Patient Advocacy and Clinical Affairs
04/03/2026
VANCOUVER, British Columbia, March 04, 2026 (GLOBE NEWSWIRE) -- NervGen Pharma Corp. (“NervGen” or the “Company") (TSXV: NGEN) (NASDAQ: NGEN), a clinical-stage biopharmaceutical company developing first-in-class [...]
NTG Nordic Transport Group Annual Report for 2025
04/03/2026
Company announcement no. 2 – 26 04 March 2026 NTG Nordic Transport Group A/S Annual Report for 2025 NTG Nordic Transport Group A/S (“NTG”) has today published the 2025 Annual Report. Selected financial highlights are [...]
Firefly Progresses Toward Development and Commercial Launch of its Foundation Model of the Human Brain Powered by NVIDIA GPU Acceleration
04/03/2026
- Company reports 20-fold expansion of commercial footprint, 33-fold increase in EEG/ERP brain scan volumes - - Harnessing increased data and cutting-edge supercomputing potentially unlocks new AI-driven biomarker [...]

Pages